ArticleTechniques in coloproctology2026
Self-expandable metal stent (SEMS) placement for malignant colonic obstruction in palliative patients: post-procedural morbidity and long-term outcomes.
Article in Techniques in coloproctology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSelf-expandable metal stents (SEMS) are recommended as a first-line treatment for malignant colonic obstruction in palliative patients. However, published outcomes remain controversial. This study aimed to evaluate the morbidity associated with SEMS placement in patients with tumor-related colonic obstruction in a palliative setting. Secondary objectives included long-term outcomes and the impact on subsequent oncological treatment.
methodsA retrospective study was conducted on 146 consecutive palliative oncological patients treated at a tertiary center between 2008 and 2023. Patients were categorized into three groups based on the cause of palliation: unresectable stage IV colon cancer (Group I), colon cancer with comorbidities and poor performance status (Group II), and extrinsic compression from extracolonic malignancies (Group III).
resultsClinical resolution of obstruction was achieved in > 80% of patients, with significant differences among groups (88% in Group I, 79% in Group II, and 59% in Group III; p = 0.009). Early morbidity occurred in 38% of cases and severe complications (≥ Clavien-Dindo III) in 31%. Morbidity was more frequent in Group III (65%). Thirty-day mortality was 15%. Only 12% of patients resumed chemotherapy after SEMS placement, with a median delay of 34 days. Median overall survival after SEMS placement was 4 months. Over 95% of patients died because of disease progression.
conclusionsSEMS placement in palliative patients is effective in relieving obstruction but carries a high risk of complications, especially in extracolonic malignancies. Less than a third of patients continue oncological treatment after stenting, highlighting the need for careful patient selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.